Although baseline exosomal PDL-1 may not correlate with clinicopathologic characteristics and melanoma tumor burden, exosomal PDL-1variations before and after treatment seem to correlate with tumor response to CPIs and to survival. The gene discussed is CD274; the disease is neoplasm.